Literature DB >> 1322791

Amsacrine and etoposide hypersensitivity of yeast cells overexpressing DNA topoisomerase II.

J L Nitiss1, Y X Liu, P Harbury, M Jannatipour, R Wasserman, J C Wang.   

Abstract

Increasing the cellular concentration of DNA topoisomerase II in yeast by expressing constitutively a plasmid-borne TOP2 gene encoding the enzyme greatly increases the sensitivity of the cells to amsacrine and etoposide (VP-16). This increased drug sensitivity at a higher intracellular DNA topoisomerase II level is observed in both RAD52+ repair-proficient strains and rad52 mutants that are defective in the repair of double-stranded breaks. These results provide strong support of the hypothesis that the cellular target of these drugs is DNA topoisomerase II, and that these drugs kill cells by converting DNA topoisomerase II into a DNA damaging agent.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1322791

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  35 in total

1.  Antitrypanosomal activity of fluoroquinolones.

Authors:  E Nenortas; C Burri; T A Shapiro
Journal:  Antimicrob Agents Chemother       Date:  1999-08       Impact factor: 5.191

2.  Chemical probes: The many genes of drug mechanism.

Authors:  Adam C Palmer
Journal:  Nat Chem Biol       Date:  2016-02       Impact factor: 15.040

3.  Tyrosyl-DNA phosphodiesterase (Tdp1) participates in the repair of Top2-mediated DNA damage.

Authors:  Karin C Nitiss; Mobeen Malik; Xiaoping He; Stephen W White; John L Nitiss
Journal:  Proc Natl Acad Sci U S A       Date:  2006-06-02       Impact factor: 11.205

4.  Endonucleolytic processing of covalent protein-linked DNA double-strand breaks.

Authors:  Matthew J Neale; Jing Pan; Scott Keeney
Journal:  Nature       Date:  2005-08-18       Impact factor: 49.962

5.  Interaction of the plasmid-encoded quinolone resistance protein Qnr with Escherichia coli DNA gyrase.

Authors:  John H Tran; George A Jacoby; David C Hooper
Journal:  Antimicrob Agents Chemother       Date:  2005-01       Impact factor: 5.191

Review 6.  Targeting DNA topoisomerase II in cancer chemotherapy.

Authors:  John L Nitiss
Journal:  Nat Rev Cancer       Date:  2009-04-20       Impact factor: 60.716

7.  Opposing effects of target overexpression reveal drug mechanisms.

Authors:  Adam C Palmer; Roy Kishony
Journal:  Nat Commun       Date:  2014-07-01       Impact factor: 14.919

8.  Trapped topoisomerase II initiates formation of de novo duplications via the nonhomologous end-joining pathway in yeast.

Authors:  Nicole Stantial; Anna Rogojina; Matthew Gilbertson; Yilun Sun; Hannah Miles; Samantha Shaltz; James Berger; Karin C Nitiss; Sue Jinks-Robertson; John L Nitiss
Journal:  Proc Natl Acad Sci U S A       Date:  2020-10-12       Impact factor: 11.205

9.  Dual functions of the homeoprotein DLX4 in modulating responsiveness of tumor cells to topoisomerase II-targeting drugs.

Authors:  Bon Q Trinh; Song Yi Ko; Nicolas Barengo; Shiaw-Yih Lin; Honami Naora
Journal:  Cancer Res       Date:  2012-12-07       Impact factor: 12.701

10.  Upregulation of topoisomerase IIalpha expression in advanced gallbladder carcinoma: a potential chemotherapeutic target.

Authors:  Mitsutsune Washiro; Masayuki Ohtsuka; Fumio Kimura; Hiroaki Shimizu; Hiroyuki Yoshidome; Takashi Sugimoto; Naohiko Seki; Masaru Miyazaki
Journal:  J Cancer Res Clin Oncol       Date:  2008-01-17       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.